<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605085</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-302</org_study_id>
    <nct_id>NCT00605085</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of the Japanese Encephalitis Vaccine IC51</brief_title>
  <official_title>Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <brief_summary>
    <textblock>
      The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine
      IC51 with an inactive control in healthy subjects aged &gt; or = 18 years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability up to Day 56</measure>
    <time_frame>Day 56</time_frame>
    <description>calculation based on safety population, numbers provide percentages of participants with Adverse Events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of Serious Adverse Events and Medically Attended Adverse Events</measure>
    <time_frame>until Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Laboratory Parameters</measure>
    <time_frame>until Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCR and GMT of Subjects With Concomitant Vaccinations</measure>
    <time_frame>until Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2675</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC51</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese Encephalitis purified inactivated vaccine (IC51)</intervention_name>
    <description>IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Written informed consent obtained prior to study entry

        Exclusion Criteria:

          -  Use of any other investigational or non-registered drug or vaccine in addition to the
             study vaccine during the study period or within 30 days preceding the first dose of
             study vaccine

          -  History of any previous JE vaccination (e.g. JE-VAXÂ®)

          -  Immunodeficiency including post-organ-transplantation or immunosuppressive therapy

          -  A family history of congenital or hereditary immunodeficiency

          -  History of autoimmune disease

          -  Any acute infections within 2 weeks prior to enrollment

          -  Known or suspected HIV Infection

          -  Pregnancy, lactation or unreliable contraception in female subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Kaltenboeck, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>June 1, 2012</results_first_submitted>
  <results_first_submitted_qc>October 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2012</results_first_posted>
  <last_update_submitted>October 19, 2012</last_update_submitted>
  <last_update_submitted_qc>October 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <organization>Intercell AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2012"/>
                <participants group_id="P2" count="663"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1962"/>
                <participants group_id="P2" count="638"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1993"/>
            <count group_id="B2" value="657"/>
            <count group_id="B3" value="2650"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="13.3"/>
                    <measurement group_id="B2" value="33.4" spread="13"/>
                    <measurement group_id="B3" value="33.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1088"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="1466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="905"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="1184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1236"/>
                    <measurement group_id="B2" value="406"/>
                    <measurement group_id="B3" value="1642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="463"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability up to Day 56</title>
        <description>calculation based on safety population, numbers provide percentages of participants with Adverse Events (AEs)</description>
        <time_frame>Day 56</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>IC51</title>
            <description>IC51</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability up to Day 56</title>
          <description>calculation based on safety population, numbers provide percentages of participants with Adverse Events (AEs)</description>
          <population>Safety Population</population>
          <units>percentage of participants with AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1993"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Serious Adverse Events and Medically Attended Adverse Events</title>
        <time_frame>until Day 56</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Laboratory Parameters</title>
        <time_frame>until Day 56</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SCR and GMT of Subjects With Concomitant Vaccinations</title>
        <time_frame>until Day 56</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safet population (N = 2650): All subjects who entered the study and received at least one vaccination. All analyses based on the safety population were carried out using the actual treatment received.
The safety population was used for all safety and tolerability analyses and for the analysis of demographic and background data.</desc>
      <group_list>
        <group group_id="E1">
          <title>IC51</title>
          <description>IC51</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Face Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa Uteri Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Ovarian Torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Curculatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="917" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="248" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="311" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="559" subjects_at_risk="1993"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Intercell AG</organization>
      <phone>+43 1 206 20 ext 1175</phone>
      <email>kdubischar-kastner@intercell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

